# Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer

> **NCT05491083** · PHASE1,PHASE2 · RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 51 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab & ADG106 (Phase Ib)
- **DRUG:** Pembrolizumab & ADG106 (Phase II)

## Key facts

- **NCT ID:** NCT05491083
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-12
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2025-07-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05491083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05491083, "Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05491083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*